Long lasting clinical response to chemotherapy for advanced uterine leiomyosarcoma: a case report
| Autor: | A. Polselli, Carlotta Santelmo, Giuseppe Pasini, Eleonora Barzotti, Claudio Ridolfi, Fabrizio Drudi, Alberto Ravaioli |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Medicine(all)
Oncology medicine.medical_specialty Chemotherapy Ifosfamide business.industry medicine.medical_treatment lcsh:R lcsh:Medicine Response Case Report General Medicine Disease Gemcitabine Docetaxel Quality of life Surgical oncology Internal medicine medicine Doxorubicin business Advanced leiomyosarcoma medicine.drug |
| Zdroj: | Journal of Medical Case Reports Journal of Medical Case Reports, Vol 7, Iss 1, p 29 (2013) |
| ISSN: | 1752-1947 |
| DOI: | 10.1186/1752-1947-7-29 |
| Popis: | Introduction Uterine leiomyosarcoma is one of the most frequent uterine sarcomas. In the metastatic setting it is sensitive to doxorubicin, ifosfamide, gemcitabine, docetaxel and a few other drugs, but time to progression is generally short. For this reason prognosis is often poor and there are few reports in the literature of long responders. Case presentation We report a case of a 40-year-old Caucasian woman with metastatic uterine leiomyosarcoma who began treatment six years before the presentation of this case report and for the following six years underwent ten lines of chemotherapy, achieving excellent results and a good quality of life. Among the treatments administered we observed a long response to temolozomide, an unconventional drug for this kind of disease. Conclusion Although there are few chemotherapeutic options for the management of metastatic uterine leiomyosarcoma, a small number of patients have an unexpected long lasting response to treatment. For this reason further research is needed to identify new therapeutic agents and the predictive factors for the achievement of response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink